The FDA said Wednesday that new production of Johnson & Johnson's Covid-19 vaccine remains paused at the Emergent BioSolutions facility where millions of potential doses were contaminated, and the agency and the company are working through a list of potential quality issues. … newly released document details issues that could affect quality during manufacturing -- including incomplete investigations into cross-contamination, written procedures that weren't followed, poorly maintained facilities and a lack of employee training.